The development of multidrug resistance to cancer chemotherapy is a major obstacle to the effective treatment of human malignancies. It has been established that membrane proteins, notably multidrug resistance (MDR), multidrug resistance protein (MRP), and breast cancer resistance protein (BCRP) of the ATP binding cassette (ABC) transporter family encoding efflux pumps, play important roles in the development of multidrug resistance. Overexpression of these transporters has been observed frequently in many types of human malignancies and correlated with poor responses to chemotherapeutic agents. Evidence has accumulated showing that redox signals are activated in response to drug treatments that affect the expression and activity of these transporters by multiple mechanisms, including (a) conformational changes in the transporters, (b) regulation of the biosynthesis cofactors required for the transporter's function, (c) regulation of the expression of transporters at transcriptional, posttranscriptional, and epigenetic levels, and (d) amplification of the copy number of genes encoding these transporters. This review describes various specific factors and their relevant signaling pathways that are involved in the regulation. Finally, the roles of redox signaling in the maintenance and evolution of cancer stem cells and their implications in the development of intrinsic and acquired multidrug resistance in cancer chemotherapy are discussed. Antioxid. Redox Signal. 11, 99–133.
AbbottBL, ColapietroAM, BarnesY, MariniF, AndreeffM, SorrentinoBP. Low levels of ABCG2 expression in adult AML blast samples. Blood, 100:4594–4601. 2002.
2.
AbolhodaA, WilsonAE, RossH, DanenbergPV, BurtM, ScottoKW. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res, 5:3352–3356. 1999.
3.
AdachiT, NakagawaH, ChungI, HagiyaY, HoshijimaK, NoguchiN, KuoMT, IshikawaT. Nrf2–dependent and -independent induction of ABC transporters ABCC1, ABCC2, and ABCG2 in HepG2 cells under oxidative stress. J Exp Ther Oncol, 6:335–348. 2007.
4.
AleksunesLM, SlittAL, MaherJM, AugustineLM, GoedkenMJ, ChanJY, CherringtonNJ, KlaassenCD, ManautouJE. Induction of Mrp3 and Mrp4 transporters during acetaminophen hepatotoxicity is dependent on Nrf2. Toxicol Appl Pharmacol, 226:7483. 2008.
5.
AllikmetsR, SchrimlLM, HutchinsonA, Romano-SpicaV, DeanM. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res, 58:5337–5339. 1998.
6.
AlviAJ, ClaytonH, JoshiC, EnverT, AshworthA, VivancoMM, DaleTC, SmalleyMJ. Functional and molecular characterisation of mammary side population cells. Breast Cancer Res, 5:R1–R8. 2003.
7.
ArbachH, ViglaskyV, LefeuF, GuinebretiereJM, RamirezV, BrideN, BoualagaN, BauchetT, PeyratJP, MathieuMC, MourahS, PodgorniakMP, SeignerinJM, TakadaK, JoabI. Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol)J Viol, 80:845–853. 2006.
8.
AtharM, TangX, LeeJL, KopelovichL, KimAL. Hedgehog signaling in skin development and cancer. Exp Dermatol, 15:667–677. 2006.
9.
AwasthiYC, SharmaR, YadavS, DwivediS, SharmaA, AwasthiS. The non-ABC drug transporter RLIP76 (RALBP-1) plays a major role in the mechanisms of drug resistance. Curr Drug Metab, 8:315–323. 2007.
10.
BacsiA, KannanS, LeeMS, HazraTK, BoldoghI. Modulation of DNA-dependent protein kinase activity in chlorambucil-treated cells1. Free Radic Biol Med, 39:1650–1659. 2005.
BakerEK, El-OstaA. MDR1, chemotherapy and chromatin remodeling. Cancer Biol Ther, 3:819–824. 2004.
13.
BakerEK, JohnstoneRW, ZalcbergJR, El OstaA. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene, 24:8061–8075. 2005.
14.
BakosE, EversR, SzakacsG, TusnadyGE, WelkerE, SzaboK, de HM vanDL, BorstP, VaradiA, SarkadiB. Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. J Biol Chem, 273:32167–32175. 1998.
15.
BandlerPE, WestlakeCJ, GrantCE, ColeSP, DeeleyRG. Identification of regions required for apical membrane localization of human multidrug resistance protein (MRP2)Mol Pharmacol, 74:9–19. 2008.
16.
BaoJJ, LeeBP, StephensLC, SahinAA, VanNT, JohnstonDA, OuCN, KuoMT. Elevated expression of hepatic proliferative markers during early hepatocarcinogenesis in hepatitis-B virus transgenic mice lacking mdr1a-encoded P-glycoprotein. Mol Carcinog, 29:103–111. 2000.
17.
BaoS, WuQ, McLendonRE, HaoY, ShiQ, HjelmelandAB, DewhirstMW, BignerDD, RichJN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444:756–760. 2006.
18.
BarancikM, BohacovaV, SedlakJ, SulovaZ, BreierA. LY294,002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci, 29:426–434. 2006.
19.
BatesSE, BakkeS, KangM, RobeyRW, ZhaiS, ThambiP, ChenCC, PatilS, SmithT, SteinbergSM, MerinoM, GoldspielB, MeadowsB, SteinWD, ChoykeP, BalisF, FiggWD, FojoT. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clin Cancer Res, 10:4724–4733. 2004.
20.
BatesSE, RobeyR, MiyakeK, RaoK, RossDD, LitmanT. The role of half-transporters in multidrug resistance. J Bioenerg Biomembr, 33:503–511. 2001.
BenassiB, FanciulliM, FiorentinoF, PorrelloA, ChiorinoG, LodaM, ZupiG, BiroccioA. c-Myc phosphorylation is required for cellular response to oxidative stress. Mol Cell, 21:509–519. 2006.
23.
BenassiB, ZupiG, BiroccioA. Gamma-glutamylcysteine synthetase mediates the c-Myc-dependent response to antineoplastic agents in melanoma cells. Mol Pharmacol, 72:1015–1023. 2007.
24.
BhattacharyaS, DasA, MallyaK, AhmadI. Maintenance of retinal stem cells by ABCG2 is regulated by notch signaling. J Cell Sci, 120:2652–2662. 2007.
25.
BheeshmacharG, PurushotamanD, SadeH, GunasekharanV, RangarajanA, SarinA. Evidence for a role for notch signaling in the cytokine-dependent survival of activated T cells. J Immunol, 177:5041–5050. 2006.
26.
BiedlerJL, ChangTD, ScottoKW, MeleraPW, SpenglerBA. Chromosomal organization of amplified genes in multidrug-resistant Chinese hamster cells. Cancer Res, 48:3179–3187. 1988.
BloomDA, JaiswalAK. Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the release of Nrf2 from INrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response element-mediated NAD(P)H:quinone oxidoreductase-1 gene expression. J Biol Chem, 278:44675–44682. 2003.
29.
BonnetD, DickJE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med, 3:730–737. 1997.
30.
BorgAG, BurgessR, GreenLM, ScheperRJ, YinJA. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival. Br J Pharmacol, 103:1083–1091. 1998.
31.
BorstP, ElferinkRO. Mammalian ABC transporters in health and disease. Annu Rev Biol Chem, 71:537–592. 2002.
32.
BoscoboinikD, DebanneMT, StaffordAR, JungCY, GuptaRS, EpandRM. Dimerization of the P-glycoprotein in membranes. Biochim Biophys Acta, 1027:225–228. 1990.
33.
BrachtK, LiebekeM, RitterCA, GrunertR, BednarskiPJ. Correlations between the activities of 19 standard anticancer agents, antioxidative enzyme activities and the expression of ATP-binding cassette transporters: comparison with the National Cancer Institute data. Anticancer Drugs, 18:389–404. 2007.
34.
BrooksTA, O'LoughlinKL, MindermanH, BundyBN, FordLA, VredenburgMR, BernackiRJ, PriebeW, BaerMR. The 4′-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells. Invest New Drugs, 25:115–122. 2007.
35.
BrownPC, TlstyTD, SchimkeRT. Enhancement of methotrexate resistance and dihydrofolate reductase gene amplification by treatment of mouse 3T6 cells with hydroxyurea. Mol Cell Biol, 3:1097–1107. 1983.
36.
BroxtermanHJ, SonneveldP, van PuttenWJ, LankelmaJ, EekmanCA, OssenkoppeleGJ, PinedoHM, LowenbergB, SchuurhuisGJ. P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy. Leukemia, 14:1018–1024. 2000.
37.
BruggeJ, HungMC, MillsGB. A new mutational AK-Tivation in the PI3K pathway. Cancer Cell, 12:104–107. 2007.
BuntingKD. ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells, 20:11–20. 2002.
40.
BurmaS, ChenBP, ChenDJ. Role of non-homologous end joining (NHEJ) in maintaining genomic integrity. DNA Repair (Amst), 5:1042–1048. 2006.
41.
CeruttiPA. Prooxidant states and tumor promotion. Science (New York), 227:375–381. 1985.
42.
ChanK, HanXD, KanYW. An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc Natl Acad Sci U S A, 98:4611–4616. 2001.
43.
ChandelNS, BudingerGR. The cellular basis for diverse responses to oxygen. Free Radic Biol Med, 42:165–174. 2007.
44.
ChariNS, McDonnellTJ. The sonic hedgehog signaling network in development and neoplasia. Adv Anat Pathol, 14:344–352. 2007.
45.
ChaudharyPM, RoninsonIB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell, 66:85–94. 1991.
46.
ChearwaeW, ShuklaS, LimtrakulP, AmbudkarSV. Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. Mol Cancer Ther, 5:1995–2006. 2006.
47.
ChenQ, YangY, LiL, ZhangJT. The amino terminus of the human multidrug resistance transporter ABCC1 has a U-shaped folding with a gating function. J Biol Chem, 281:31152–31163. 2006.
48.
ChenY, YangY, MillerML, ShenD, ShertzerHG, StringerKF, WangB, SchneiderSN, NebertDW, DaltonTP. Hepatocyte-specific Gclc deletion leads to rapid onset of steatosis with mitochondrial injury and liver failure. Hepatology, 45:1118–1128. 2007.
49.
ChiKN, ChiaSK, DixonR, NewmanMJ, WacherVJ, SikicB, GelmonKA. A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Invest New Drugs, 23:311–315. 2005.
50.
ChibaT, KitaK, ZhengYW, YokosukaO, SaishoH, IwamaA, NakauchiH, TaniguchiH. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology, 44:240–251. 2006.
ColeSP, BhardwajG, GerlachJH, MackieJE, GrantCE, AlmquistKC, StewartAJ, KurzEU, DuncanAM, DeeleyRG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (New York), 258:1650–1654. 1992.
53.
ColeSP, DeeleyRG. Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol Sci, 27:438–446. 2006.
54.
CollinsAT, BerryPA, HydeC, StowerMJ, MaitlandNJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res, 65:10946–10951. 2005.
55.
ComerfordKM, WallaceTJ, KarhausenJ, LouisNA, MontaltoMC, ColganSP. Hypoxia-inducible factor-1–dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res, 62:3387–3394. 2002.
56.
CoppleIM, GoldringCE, KitteringhamNR, ParkBK. The Nrf2–Keap1 defence pathway: role in protection against drug-induced toxicity. Toxicology, 246:24–33. 2008.
57.
de la PeñaP, BornsteinB, del HoyoP, Fernandez-MorenoMA, MartinMA, CamposY, Gomez-EscalonillaC, MolinaJA, CabelloA, ArenasJ, GaresseR. Mitochondrial dysfunction associated with a mutation in the Notch3 gene in a CADASIL family. Neurology, 57:1235–1238. 2001.
58.
DeanM, FojoT, BatesS. Tumour stem cells and drug resistance. Nat Rev Cancer, 5:275–284. 2005.
59.
DeeleyRG, ColeSP. Substrate recognition and transport by multidrug resistance protein 1 (ABCC1)FEBS Lett, 580:1103–1111. 2006.
60.
DeisserothAB. Clinical trials involving multidrug resistance transcription units in retroviral vectors. Clin Cancer Res, 5:1607–1609. 1999.
61.
DengL, Lin-LeeYC, ClaretFX, KuoMT. 2–Acetylaminofluorene up-regulates rat mdr1b expression through generating reactive oxygen species that activate NF-kappa B pathway. J Biol Chem, 276:413–420. 2001.
62.
DhakshinamoorthyS, JaiswalAK. Functional characterization and role of INrf2 in antioxidant response element-mediated expression and antioxidant induction of NAD(P)H:quinone oxidoreductase gene. Oncogene, 20:3906–3917. 2001.
DoladoI, SwatA, AjenjoN, De VitaG, CuadradoA, NebredaAR. p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis1. Cancer Cell, 11:191–205. 2007.
65.
DoyleLA, YangW, AbruzzoLV, KrogmannT, GaoY, RishiAK, RossDD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A, 95:15665–15670. 1998.
66.
EePL, KamalakaranS, TonettiD, HeX, RossDD, BeckWT. Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer Res, 64:1247–1251. 2004.
67.
EllgaardL, RuddockLW. The human protein disulphide isomerase family: substrate interactions and functional properties. EMBO Rep, 6:28–32. 2005.
68.
EllisenLW, BirdJ, WestDC, SorengAL, ReynoldsTC, SmithSD, SklarJ. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell, 66:649–661. 1991.
69.
EssersMA, de Vries-SmitsLM, BarkerN, PoldermanPE, BurgeringBM, KorswagenHC. Functional interaction between beta-catenin and FOXO in oxidative stress signaling. Science (New York), 308:1181–1184. 2005.
FojoAT, UedaK, SlamonDJ, PoplackDG, GottesmanMM, PastanI. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A, 84:265–269. 1987.
72.
FojoT. p53 as a therapeutic target: unresolved issues on the road to cancer therapy targeting mutant p53. Drug Resist Update, 5:209–216. 2002.
73.
FrankNY, MargaryanA, HuangY, SchattonT, Waaga-GasserAM, GasserM, SayeghMH, SadeeW, FrankMH. ABCB5–mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res, 65:4320–4333. 2005.
74.
FriedmanJS, RebelVI, DerbyR, BellK, HuangTT, KuypersFA, EpsteinCJ, BurakoffSJ. Absence of mitochondrial superoxide dismutase results in a murine hemolytic anemia responsive to therapy with a catalytic antioxidant. J Exp Med, 193:925–934. 2001.
75.
GhoshS, KarinM. Missing pieces in the NF-kappaB puzzle. Cell, 109,suppl:S81–S96. 2002.
76.
GilJ, StembalskaA, PeszKA, SasiadekMM. Cancer stem cells: the theory and perspectives in cancer therapy. J Appl Genet, 49:193–199. 2008.
77.
GomiA, MasuzawaT, IshikawaT, KuoMT. Posttranscriptional regulation of MRP/GS-X pump and gammaglutamylcysteine synthetase expression by 1–(4–amino-2–methyl-5–pyrimidinyl) methyl-3–(2–chloroethyl)-3–nitrosourea and by cycloheximide in human glioma cells. Biochem Biophys Res Commun, 239:51–56. 1997.
78.
GoodellMA, BroseK, ParadisG, ConnerAS, MulliganRC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med, 183:1797–1806. 1996.
79.
GortEH, GrootAJ, Derks van de VenTL, van der GroepP, VerlaanI, van LaarT, van DiestPJ, van der WallE, ShvartsA. Hypoxia-inducible factor-1alpha expression requires PI 3–kinase activity and correlates with Akt1 phosphorylation in invasive breast carcinomas. Oncogene, 25:6123–6127. 2006.
80.
GotohY, CooperJA. Reactive oxygen species- and dimerization-induced activation of apoptosis signal-regulating kinase 1 in tumor necrosis factor-alpha signal transduction. J Biol Chem, 273:17477–17482. 1998.
81.
GreenbergPL, LeeSJ, AdvaniR, TallmanMS, SikicBI, LetendreL, DuganK, LumB, ChinDL, DewaldG, PaiettaE, BennettJM, RoweJM. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)J Clin Oncol, 22:1078–1086. 2004.
82.
GretenFR, EckmannL, GretenTF, ParkJM, LiZW, EganLJ, KagnoffMF, KarinM. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell, 118:285–296. 2004.
83.
GruberCW, CemazarM, HerasB, MartinJL, CraikDJ. Protein disulfide isomerase: the structure of oxidative folding. Trends Biochem Sci, 31:455–464. 2006.
84.
GuoY, KotovaE, ChenZS, LeeK, Hopper-BorgeE, BelinskyMG, KruhGD. MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2′,3′-dideoxycytidine and 9′-(2′-phosphonylmethoxyethyl)adenine. J Biol Chem, 278:29509–29514. 2003.
85.
GuzyRD, MackMM, SchumackerPT. Mitochondrial complex III is required for hypoxia-induced ROS production and gene transcription in yeast. Antioxid Redox Signal, 9:1317–1328. 2007.
86.
HalimAB, LeGrosL, GellerA, KotbM. Expression and functional interaction of the catalytic and regulatory subunits of human methionine adenosyltransferase in mammalian cells. J Biol Chem, 274:29720–29725. 1999.
87.
HamiltonD, WuJH, Aoui-JamaliM, BatistG. A novel missense mutation in the gamma-glutamylcysteine synthetase catalytic subunit gene causes both decreased enzymatic activity and glutathione production. Blood, 102:725–730. 2003.
88.
HananiaEG, GilesRE, KavanaghJ, FuSQ, EllersonD, ZuZ, WangT, SuY, KudelkaA, RahmanZ, HolmesF, HortobagyiG, ClaxtonD, BachierC, ThallP, ChengS, HesterJ, OstroveJM, BirdRE, ChangA, KorblingM, SeongD, CoteR, HolzmayerT, MechetnerE, HeimfeldS, BerensonR, BurtnessB, EdwardsC, BestR, AndreeffM, ChamplinR, DeisserothAB. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci U S A, 93:15346–15351. 1996.
89.
HansonS, KimE, DeppertW. Redox factor 1 (Ref-1) enhances specific DNA binding of p53 by promoting p53 tetramerization. Oncogene, 24:1641–1647. 2005.
90.
HaraguchiN, InoueH, TanakaF, MimoriK, UtsunomiyaT, SasakiA, MoriM. Cancer stem cells in human gastrointestinal cancers. Hum Cell, 19:24–29. 2006.
91.
HayashiA, SuzukiH, ItohK, YamamotoM, SugiyamaY. Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance-associated protein 1 in mouse embryo fibroblasts. Biochem Biophys Res Commun, 310:824–829. 2003.
92.
HellmanA, ZlotorynskiE, SchererSW, CheungJ, VincentJB, SmithDI, TrakhtenbrotL, KeremB. A role for common fragile site induction in amplification of human oncogenes. Cancer Cell, 1:89–97. 2002.
93.
HenriksenU, FogJU, LitmanT, GetherU. Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2. J Biol Chem, 280:36926–36934. 2005.
94.
HesdorfferC, AyelloJ, WardM, KaubischA, VahdatL, BalmacedaC, GarrettT, FetellM, ReissR, BankA, AntmanK. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol, 16:165–172. 1998.
HoMM, HoggeDE, LingV. MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. Exp Hematol, 36:433–442. 2008.
97.
HoMM, NgAV, LamS, HungJY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res, 67:4827–4833. 2007.
98.
HolstB, TachibanaC, WintherJR. Active site mutations in yeast protein disulfide isomerase cause dithiothreitol sensitivity and a reduced rate of protein folding in the endoplasmic reticulum. J Cell Biol, 138:1229–1238. 1997.
99.
HonWC, WilsonMI, HarlosK, ClaridgeTD, SchofieldCJ, PughCW, MaxwellPH, RatcliffePJ, StuartDI, JonesEY. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature, 417:975–978. 2002.
100.
HoughtonPJ, GermainGS, HarwoodFC, SchuetzJD, StewartCF, BuchdungerE, TraxlerP. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res, 64:2333–2337. 2004.
101.
HuangHC, NguyenT, PickettCB. Regulation of the antioxidant response element by protein kinase C-mediated phosphorylation of NF-E2–related factor 2. Proc Natl Acad Sci U S A, 97:12475–12480. 2000.
102.
HudsonCC, LiuM, ChiangGG, OtternessDM, LoomisDC, KaperF, GiacciaAJ, AbrahamRT. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol, 22:7004–7014. 2002.
103.
HwangC, SinskeyAJ, LodishHF. Oxidized redox state of glutathione in the endoplasmic reticulum. Science (New York), 257:1496–1502. 1992.
104.
HyrienO, DebatisseM, ButtinG, deSV. The multicopy appearance of a large inverted duplication and the sequence at the inversion joint suggest a new model for gene amplification. EMBO J, 7:407–417. 1988.
105.
IchijoH, NishidaE, IrieK, tenDP, SaitohM, MoriguchiT, TakagiM, MatsumotoK, MiyazonoK, GotohY. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science (New York), 275:90–94. 1997.
106.
IkegamiY, TatebeS, Lin-LeeYC, XieQW, IshikawaT, KuoMT. Induction of MRP1 and gamma-glutamylcysteine synthetase gene expression by interleukin 1beta is mediated by nitric oxide-related signalings in human colorectal cancer cells. J Cell Physiol, 185:293–301. 2000.
107.
IshikawaK, TakenagaK, AkimotoM, KoshikawaN, YamaguchiA, ImanishiH, NakadaK, HonmaY, HayashiJ. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science (New York), 320:661–664. 2008.
IshikawaT, BaoJJ, YamaneY, AkimaruK, FrindrichK, WrightCD, KuoMT. Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem, 271:14981–14988. 1996.
110.
ItoK, HiraoA, AraiF, MatsuokaS, TakuboK, HamaguchiI, NomiyamaK, HosokawaK, SakuradaK, NakagataN, IkedaY, MakTW, SudaT. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells4. Nature, 431:997–1002. 2004.
111.
ItoK, HiraoA, AraiF, TakuboK, MatsuokaS, MiyamotoK, OhmuraM, NakaK, HosokawaK, IkedaY, SudaT. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med, 12:446–451. 2006.
112.
ItohK, WakabayashiN, KatohY, IshiiT, IgarashiK, EngelJD, YamamotoM. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev, 13:76–86. 1999.
113.
JedlitschkyG, LeierI, BuchholzU, CenterM, KepplerD. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res, 54:4833–4836. 1994.
114.
JinS, ScottoKW. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. Mol Cell Biol, 18:4377–4384. 1998.
115.
JonkerJW, BuitelaarM, WagenaarE, van deV, SchefferGL, ScheperRJ, PloschT, KuipersF, ElferinkRP, RosingH, BeijnenJH, SchinkelAH. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A, 99:15649–15654. 2002.
KageK, FujitaT, SugimotoY. Role of Cys-603 in dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2. Cancer Sci, 96:866–872. 2005.
118.
KaranjawalaZE, MurphyN, HintonDR, HsiehCL, LieberMR. Oxygen metabolism causes chromosome breaks and is associated with the neuronal apoptosis observed in DNA double-strand break repair mutants. Curr Biol, 12:397–402. 2002.
119.
KarinM, CaoY, GretenFR, LiZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer, 2:301–310. 2002.
120.
KartenbeckJ, LeuschnerU, MayerR, KepplerD. Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology, 23:1061–1066. 1996.
121.
KarwatskyJ, LeimanisM, CaiJ, GrosP, GeorgesE. The leucotriene C4 binding sites in multidrug resistance protein 1 (ABCC1) include the first membrane multiple spanning domain. Biochemistry, 44:340–351. 2005.
122.
KauffmannHM, PfannschmidtS, ZollerH, BenzA, VorderstemannB, WebsterJI, SchrenkD. Influence of redoxactive compounds and PXR-activators on human MRP1 and MRP2 gene expression. Toxicology, 171:137–146. 2002.
123.
KawaharaBT, QuinnMT, LambethJD. Molecular evolution of the reactive oxygen-generating NADPH oxidase (Nox/Duox) family of enzymes. Br Med C Evol Biol, 7:109. 2007.
KimM, TurnquistH, JacksonJ, SgagiasM, YanY, GongM, DeanM, SharpJG, CowanK. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res, 8:22–28. 2002.
126.
KlementJF, MatsuzakiY, JiangQJ, TerlizziJ, ChoiHY, FujimotoN, LiK, PulkkinenL, BirkDE, SundbergJP, UittoJ. Targeted ablation of the abcc6 gene results in ectopic mineralization of connective tissues. Mol Cell Biol, 25:8299–8310. 2005.
127.
KobayashiA, KangMI, WataiY, TongKI, ShibataT, UchidaK, YamamotoM. Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Mol Cell Biol, 26:221–229. 2006.
128.
KrishnamurthyP, RossDD, NakanishiT, Bailey-DellK, ZhouS, MercerKE, SarkadiB, SorrentinoBP, SchuetzJD. The stem cell marker BCRP/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem, 279:24218–24225. 2004.
129.
KrishnamurthyP, SchuetzJD. Role of ABCG2/BCRP in biology and medicine. Annu Rev Pharmacol Toxicol, 46:381–410. 2006.
130.
KrishnamurthyP, XieT, SchuetzJD. The role of transporters in cellular heme and porphyrin homeostasis. Pharmacol Ther, 114:345–358. 2007.
131.
KruhGD, BelinskyMG. The MRP family of drug efflux pumps. Oncogene, 22:7537–7552. 2003.
132.
KumarA, MarquesM, CarreraAC. Phosphoinositide 3–kinase activation in late G1 is required for c-Myc stabilization and S phase entry. Mol Cell Biol, 26:9116–9125. 2006.
133.
KuoMT. Expression of multidrug-resistance (P-glycoprotein) genes in liver cancers: a molecular example of the convergence theory of hepatocarcinogenesis?Mol Carcinog, 7:73–75. 1993.
134.
KuoMT. Roles of multidrug resistance genes in breast cancer chemoresistance. Adv Exp Med Biol, 608:23–30. 2007.
135.
KuoMT, BaoJ, FuruichiM, YamaneY, GomiA, SavarajN, MasuzawaT, IshikawaT. Frequent coexpression of MRP/GS-X pump and gamma-glutamylcysteine synthetase mRNA in drug-resistant cells, untreated tumor cells, and normal mouse tissues. Biochem Pharmacol, 55:605–615. 1998.
136.
KuoMT, BaoJJ, CurleySA, IkeguchiM, JohnstonDA, IshikawaT. Frequent coordinated overexpression of the MRP/GS-X pump and gamma-glutamylcysteine synthetase genes in human colorectal cancers. Cancer Res, 56:3642–3644. 1996.
137.
KuoMT, LiuZ, WeiY, Lin-LeeYC, TatebeS, MillsGB, UnateH. Induction of human MDR1 gene expression by 2–acetylaminofluorene is mediated by effectors of the phosphoinositide 3–kinase pathway that activate NF-kappaB signaling. Oncogene, 21:1945–1954. 2002.
138.
KuoMT, SenS, HittelmanWN, HsuTC. Chromosomal fragile sites and DNA amplification in drug-resistant cells. Biochem Pharmacol, 56:7–13. 1998.
139.
KuoMT, VyasRC, JiangLX, HittelmanWN. Chromosome breakage at a major fragile site associated with P-glycoprotein gene amplification in multidrug-resistant CHO cells. Mol Cell Biol, 14:5202–5211. 1994.
140.
LambethJD, KawaharaT, DieboldB. Regulation of Nox and Duox enzymatic activity and expression. Free Radic Biol Med, 43:319–331. 2007.
LapidotT, SirardC, VormoorJ, MurdochB, HoangT, Caceres-CortesJ, MindenM, PatersonB, CaligiuriMA, DickJE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 367:645–648. 1994.
143.
LeLH, MooreMJ, SiuLL, OzaAM, MacLeanM, FisherB, ChaudharyA, de AlwisDP, SlapakC, SeymourL. Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours. Cancer Chemother Pharmacol, 56:154–160. 2005.
144.
LeeJM, HansonJM, ChuWA, JohnsonJA. Phosphatidylinositol 3–kinase, not extracellular signal-regulated kinase, regulates activation of the antioxidant-responsive element in IMR-32 human neuroblastoma cells. J Biol Chem, 276:20011–20016. 2001.
145.
LeggasM, AdachiM, SchefferGL, SunD, WielingaP, DuG, MercerKE, ZhuangY, PanettaJC, JohnstonB, ScheperRJ, StewartCF, SchuetzJD. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol, 24:7612–7621. 2004.
146.
LegouyE, FossarN, LhomondG, BrisonO. Structure of four amplified DNA novel joints. Somat Cell Mol Genet, 15:309–320. 1989.
147.
LeierI, JedlitschkyG, BuchholzU, CenterM, ColeSP, DeeleyRG, KepplerD. ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump. Biochem J, 314:433–437. 1996.
148.
LeierI, JedlitschkyG, BuchholzU, ColeSP, DeeleyRG, KepplerD. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem, 269:27807–27810. 1994.
149.
LeonardGD, FojoT, BatesSE. The role of ABC transporters in clinical practice. Oncologist, 8:411–424. 2003.
150.
LertratanangkoonK, WuCJ, SavarajN, ThomasML. Alterations of DNA methylation by glutathione depletion. Cancer Lett, 120:149–156. 1997.
151.
LeslieEM, BowersRJ, DeeleyRG, ColeSP. Structural requirements for functional interaction of glutathione tripeptide analogs with the human multidrug resistance protein 1 (MRP1)J Pharmacol Exp Ther, 304:643–653. 2003.
152.
LeslieEM, ItoK, UpadhyayaP, HechtSS, DeeleyRG, ColeSP. Transport of the beta-O-glucuronide conjugate of the tobacco-specific carcinogen 4–(methylnitrosamino)-1–(3–pyridyl)-1–butanol (NNAL) by the multidrug resistance protein 1 (MRP1): requirement for glutathione or a non-sulfur-containing analog. J Biol Chem, 276:27846–27854. 2001.
153.
LeslieEM, LetourneauIJ, DeeleyRG, ColeSP. Functional and structural consequences of cysteine substitutions in the NH2 proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1)Biochemistry, 42:5214–5224. 2003.
154.
LevineAJ, HuW, FengZ. The P53 pathway: what questions remain to be explored?Cell Death Differ, 13:1027–1036. 2006.
155.
Lin-LeeYC, TatebeS, SavarajN, IshikawaT, TienKM. Differential sensitivities of the MRP gene family and gamma-glutamylcysteine synthetase to prooxidants in human colorectal carcinoma cell lines with different p53 status. Biochem Pharmacol, 61:555–563. 2001.
156.
LiuB, ChenY, St ClairDK. ROS and p53: a versatile partnership. Free Radic Biol Med, 44:1529–1535. 2008.
157.
LiuM, LiD, AnejaR, JoshiHC, XieS, ZhangC, ZhouJ. PO(2)-dependent differential regulation of multidrug resistance 1 gene expression by the c-Jun NH2–terminal kinase pathway. J Biol Chem, 282:17581–17586. 2007.
158.
LiuY, YangY, QiJ, PengH, ZhangJT. Effect of cysteine mutagenesis on the function and disulfide bond formation of human ABCG2. J Pharmacol Exp Ther, 326:33–40. 2008.
159.
LivingstoneLR, WhiteA, SprouseJ, LivanosE, JacksT, TlstyTD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70:923–935. 1992.
160.
LoAW, SprungCN, FouladiB, PedramM, SabatierL, RicoulM, ReynoldsGE, MurnaneJP. Chromosome instability as a result of double-strand breaks near telomeres in mouse embryonic stem cells. Mol Cell Biol, 22:4836–4850. 2002.
161.
LoboNA, ShimonoY, QianD, ClarkeMF. The biology of cancer stem cells. Annu Rev Cell Dev Biol, 23:675–699. 2007.
162.
LoeDW, DeeleyRG, ColeSP. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res, 58:5130–5136. 1998.
163.
LopezdSI, FanJ, YangX, ZondermanAB, PotapovaO, PizerES, GorospeM. Role of the RNA-binding protein HuR in colon carcinogenesis. Oncogene, 22:7146–7154. 2003.
164.
LueddeT, BerazaN, KotsikorisV, van LooG, NenciA, De VosR, RoskamsT, TrautweinC, PasparakisM. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma1. Cancer Cell, 11:119–132. 2007.
165.
LuftigM, YasuiT, SoniV, KangMS, JacobsonN, Cahir-McFarlandE, SeedB, KieffE. Epstein-Barr virus latent infection membrane protein 1 TRAF-binding site induces NIK/IKK alpha-dependent noncanonical NF-kappaB activation. Proc Natl Acad Sci U S A, 101:141–146. 2004.
166.
ManciuL, ChangXB, BuyseF, HouYX, GustotA, RiordanJR, RuysschaertJM. Intermediate structural states involved in MRP1–mediated drug transport: role of glutathione. J Biol Chem, 278:3347–3356. 2003.
167.
MankhetkornS, DubruF, HesschenbrouckJ, FialloM, Garnier-SuillerotA. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8–(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. Mol Pharmacol, 49:532–539. 1996.
168.
ManoharCF, BrayJA, SalwenHR, MadafiglioJ, ChengA, FlemmingC, MarshallGM, NorrisMD, HaberM, CohnSL. MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma. Oncogene, 23:753–762. 2004.
169.
MansfieldKD, GuzyRD, PanY, YoungRM, CashTP, SchumackerPT, SimonMC. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation. Cell Metab, 1:393–399. 2005.
170.
MatsuzawaA, IchijoH. Redox control of cell fate by MAP kinase: physiological roles of ASK1–MAP kinase pathway in stress signaling. Biochim Biophys Acta, 2008.
171.
McCubreyJA, SteelmanLS, ChappellWH, AbramsSL, WongEW, ChangF, LehmannB, TerrianDM, MilellaM, TafuriA, StivalaF, LibraM, BaseckeJ, EvangelistiC, MartelliAM, FranklinRA. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta, 1773:1263–1284. 2007.
172.
MeiY, WeiD, LiuJ. Reversal of multidrug resistance in KB cells with tea polyphenol antioxidant capacity. Cancer Biol Ther, 4:468–473. 2005.
MeyersMB, SpenglerBA, ChangTD, MeleraPW, BiedlerJL. Gene amplification-associated cytogenetic aberrations and protein changes in vincristine-resistant Chinese hamster, mouse, and human cells. J Cell Biol, 100:588–597. 1985.
175.
MillerJR, HockingAM, BrownJD, MoonRT. Mechanism and function of signal transduction by the Wnt/beta-catenin and Wnt/Ca2+ pathways. Oncogene, 18:7860–7872. 1999.
176.
MindermanH, ZhouY, O'LoughlinKL, BaerMR. Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status. Cancer Chemother Pharmacol, 60:245–255. 2007.
177.
MiuraK, YoshiuraK, MiuraS, ShimadaT, YamasakiK, YoshidaA, NakayamaD, ShibataY, NiikawaN, MasuzakiH. A strong association between human earwax-type and apocrine colostrum secretion from the mammary gland. Hum Genet, 121:631–633. 2007.
178.
MiyakeK, MickleyL, LitmanT, ZhanZ, RobeyR, CristensenB, BrangiM, GreenbergerL, DeanM, FojoT, BatesSE. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res, 59:8–13. 1999.
179.
MogiM, YangJ, LambertJF, ColvinGA, ShiojimaI, SkurkC, SummerR, FineA, QuesenberryPJ, WalshK. Akt signaling regulates side population cell phenotype via Bcrp1 translocation. J Biol Chem, 278:39068–39075. 2003.
180.
MolnarJ, GyemantN, TanakaM, HohmannJ, Bergmann-LeitnerE, MolnarP, DeliJ, DidiziapetrisR, FerreiraMJ. Inhibition of multidrug resistance of cancer cells by natural diterpenes, triterpenes and carotenoids. Curr Pharm Des, 12:287–311. 2006.
181.
MoscowJA, HuangH, CarterC, HinesK, ZujewskiJ, CusackG, ChowC, VenzonD, SorrentinoB, ChiangY, GoldspielB, LeitmanS, ReadEJ, AbatiA, GottesmanMM, PastanI, SellersS, DunbarC, CowanKH. Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy. Blood, 94:52–61. 1999.
182.
MossinkMH, van ZonA, Franzel-LuitenE, SchoesterM, KickhoeferVA, SchefferGL, ScheperRJ, SonneveldP, WiemerEA. Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostatics. Cancer Res, 62:7298–7304. 2002.
183.
MossinkMH, van ZonA, ScheperRJ, SonneveldP, WiemerEA. Vaults: a ribonucleoprotein particle involved in drug resistance?Oncogene, 22:7458–7467. 2003.
184.
MullerM, MeijerC, ZamanGJ, BorstP, ScheperRJ, MulderNH, De VriesEG, JansenPL. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci U S A, 91:13033–13037. 1994.
185.
NarasimhaiahR, TuchmanA, LinSL, NaegeleJR. Oxidative damage and defective DNA repair is linked to apoptosis of migrating neurons and progenitors during cerebral cortex development in Ku70–deficient mice. Cereb Cortex, 15:696–707. 2005.
186.
NauglerWE, SakuraiT, KimS, MaedaS, KimK, ElsharkawyAM, KarinM. Gender disparity in liver cancer due to sex differences in MyD88–dependent IL-6 production. Science (New York), 317:121–124. 2007.
187.
NguyenT, SherrattPJ, NioiP, YangCS, PickettCB. Nrf2 controls constitutive and inducible expression of ARE-driven genes through a dynamic pathway involving nucleocytoplasmic shuttling by Keap1. J Biol Chem, 280:32485–32492. 2005.
188.
NguyenT, YangCS, PickettCB. The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. Free Radic Biol Med, 37:433–441. 2004.
189.
NobiliS, LandiniI, GiglioniB, MiniE. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets, 7:861–879. 2006.
190.
O'BrienCA, PollettA, GallingerS, DickJE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature, 445:106–110. 2007.
191.
OkunoY, HahnPJ, GilbertDM. Structure of a palindromic amplicon junction implicates microhomology-mediated end joining as a mechanism of sister chromatid fusion during gene amplification. Nucleic Acids Res, 32:749–756. 2004.
192.
OnoN, VandHI, SchefferGL, van deWK, VanDE, deHM, BoerkeA, GadellaBM, De RooijDG, NeefjesJJ, GroothuisTA, OomenL, BrocksL, IshikawaT, BorstP. Multidrug resistance-associated protein 9 (ABCC12) is present in mouse and boar sperm. Biochem J, 406:31–40. 2007.
193.
Ozvegy-LaczkaC, HegedusT, VaradyG, UjhellyO, SchuetzJD, VaradiA, KeriG, OrfiL, NemetK, SarkadiB. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol, 65:1485–1495. 2004.
PhamCG, BubiciC, ZazzeroniF, KnabbJR, PapaS, KuntzenC, FranzosoG. Upregulation of twist-1 by NF{kappa}B blocks cytotoxicity induced by chemotherapeutic drugs. Mol Cell Biol, 27:3920–3935. 2007.
196.
PhamCG, BubiciC, ZazzeroniF, PapaS, JonesJ, AlvarezK, JayawardenaS, De SmaeleE, CongR, BeaumontC, TortiFM, TortiSV, FranzosoG. Ferritin heavy chain up-regulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell, 119:529–542. 2004.
197.
PikarskyE, PoratRM, SteinI, AbramovitchR, AmitS, KasemS, Gutkovich-PyestE, Urieli-ShovalS, GalunE, Ben-NeriahY. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature, 431:461–466. 2004.
198.
PirkerR, WallnerJ, GeisslerK, LinkeschW, HaasOA, BettelheimP, HopfnerM, ScherrerR, ValentP, HavelecL, LudwigH, LechnerK. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst, 83:708–712. 1991.
199.
PlantingAS, SonneveldP, van derGA, SparreboomA, van der BurgME, LuytenGP, deLK, deBoer-Dennert M, WisselPS, JewellRC, PaulEM, PurvisNBJr, VerweijJ. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors. Cancer Chemother Pharmacol, 55:91–99. 2005.
200.
PlasschaertSL, de BontES, BoezenM, vander KolkDM, DaenenSM, FaberKN, KampsWA, de VriesEG, VellengaE. Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin Cancer Res, 11:8661–8668. 2005.
201.
PouyssegurJ, Mechta-GrigoriouF. Redox regulation of the hypoxia-inducible factor. Biol Chem, 387:1337–1346. 2006.
202.
PowisG, KirkpatrickL. Hypoxia inducible factor-1alpha as a cancer drug target. Mol Cancer Ther, 3:647–654. 2004.
203.
QianYM, GrantCE, WestlakeCJ, ZhangDW, LanderPA, ShepardRL, DantzigAH, ColeSP, DeeleyRG. Photo-labeling of human and murine multidrug resistance protein 1 with the high affinity inhibitor [125I]LY475776 and azidophenacyl-[35S]glutathione. J Biol Chem, 277:35225–35231. 2002.
204.
RandleRA, RaguzS, HigginsCF, YagueE. Role of the highly structured 5′-end region of MDR1 mRNA on P-glycoprotein expression. Biochem J, 406:445–455. 2007.
205.
RaviD, MuniyappaH, DasKC. Endogenous thioredoxin is required for redox cycling of anthracyclines and p53–dependent apoptosis in cancer cells. J Biol Chem, 280:40084–40096. 2005.
206.
ReidG, WielingaP, ZelcerN, deHM, vanDL, WijnholdsJ, BalzariniJ, BorstP. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol, 63:1094–1103. 2003.
207.
RelieneR, FischerE, SchiestlRH. Effect of N-acetyl cysteine on oxidative DNA damage and the frequency of DNA deletions in atm-deficient mice1. Cancer Res, 64:5148–5153. 2004.
208.
RelieneR, GoadME, SchiestlRH. Developmental cell death in the liver and newborn lethality of Ku86 deficient mice suppressed by antioxidant N-acetyl-cysteine. DNA Repair (Amst), 5:1392–1397. 2006.
209.
RenXQ, FurukawaT, NakajimaY, TakahashiH, AokiS, SumizawaT, HaraguchiM, KobayashiM, ChijiiwaK, AkiyamaS. GSH inhibits trypsinization of the C-terminal half of human MRP1. J Biol Chem, 280:6231–6237. 2005.
210.
RenesJ, de VriesEG, NienhuisEF, JansenPL, MullerM. ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br J Pharmacol, 126:681–688. 1999.
211.
RiceGC, HoyC, SchimkeRT. Transient hypoxia enhances the frequency of dihydrofolate reductase gene amplification in Chinese hamster ovary cells3. Proc Natl Acad Sci U S A, 83:5978–5982. 1986.
212.
RichJN. Cancer stem cells in radiation resistance. Cancer Res, 67:8980–8984. 2007.
213.
RistoffE, AugustsonC, GeisslerJ, deRT, CarlssonK, LuoJL, AnderssonK, WeeningRS, vanZR, LarssonA, RoosD. A missense mutation in the heavy subunit of gamma-glutamylcysteine synthetase gene causes hemolytic anemia. Blood, 95:2193–2196. 2000.
214.
RobeyRW, PolgarO, DeekenJ, ToKW, BatesSE. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev, 26:39–57. 2007.
215.
RobeyRW, SteadmanK, PolgarO, MorisakiK, BlayneyM, MistryP, BatesSE. Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res, 64:1242–1246. 2004.
216.
RobeyRW, ZhanZ, PiekarzRL, KayasthaGL, FojoT, BatesSE. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176)Clin Cancer Res, 12:1547–1555. 2006.
217.
RozanLM, El-DeiryWS. p53 downstream target genes and tumor suppression: a classical view in evolution. Cell Death Differ, 14:3–9. 2007.
218.
RumpoldH, SalvadorC, WolfAM, TilgH, GastlG, WolfD. Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. Biochem Biophys Res Commun, 361:549–554. 2007.
219.
SalernoM, Garnier-SuillerotA. Kinetics of glutathione and daunorubicin efflux from multidrug resistance protein overexpressing small-cell lung cancer cells. Eur J Pharmacol, 421:1–9. 2001.
220.
SalernoM, LoechariyakulP, SaengkhaeC, Garnier-SuillerotA. Relation between the ability of some compounds to modulate the MRP1–mediated efflux of glutathione and to inhibit the MRPl-mediated efflux of daunorubicin. Biochem Pharmacol, 68:2159–2165. 2004.
221.
SampathJ, AdachiM, HatseS, NaesensL, BalzariniJ, FlatleyRM, MatherlyLH, SchuetzJD. Role of MRP4 and MRP5 in biology and chemotherapy. AAPS Pharm Sci, 4:E14. 2002.
222.
ScharenbergCW, HarkeyMA, Torok-StorbB. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood, 99:507–512. 2002.
SchefferGL, WijngaardPL, FlensMJ, IzquierdoMA, SlovakML, PinedoHM, MeijerCJ, CleversHC, ScheperRJ. The drug resistance-related protein LRP is the human major vault protein. Nat Med, 1:578–582. 1995.
225.
SchinkelAH, MayerU, WagenaarE, MolCA, van DeemterL, SmitJJ, van der ValkMA, VoordouwAC, SpitsH, van TellingenO, ZijlmansJM, FibbeWE, BorstP. Normal viability and altered pharmacokinetics in mice lacking mdr1–type (drug-transporting) P-glycoproteins3. Proc Natl Acad Sci U S A, 94:4028–4033. 1997.
226.
SchinkelAH, MolCA, WagenaarE, vanDL, SmitJJ, BorstP. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer, 31A:1295–1298. 1995.
227.
SchoenleinPV, ShenDW, BarrettJT, PastanI, GottesmanMM. Double minute chromosomes carrying the human multidrug resistance 1 and 2 genes are generated from the dimerization of submicroscopic circular DNAs in colchicine-selected KB carcinoma cells. Mol Biol Cell, 3:507–520. 1992.
228.
SchuetzJD, ConnellyMC, SunD, PaibirSG, FlynnPM, SrinivasRV, KumarA, FridlandA. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med, 5:1048–1051. 1999.
229.
ScottoKW. Transcriptional regulation of ABC drug transporters. Oncogene, 22:7496–7511. 2003.
230.
SeemannS, HainautP. Roles of thioredoxin reductase 1 and APE/Ref-1 in the control of basal p53 stability and activity. Oncogene, 24:3853–3863. 2005.
231.
SekharKR, SoltaninassabSR, BorrelliMJ, XuZQ, MeredithMJ, DomannFE, FreemanML. Inhibition of the 26S proteasome induces expression of GLCLC, the catalytic subunit for gamma-glutamylcysteine synthetase. Biochem Biophys Res Commun, 270:311–317. 2000.
232.
SellersSE, TisdaleJF, AgricolaBA, MetzgerME, DonahueRE, DunbarCE, SorrentinoBP. The effect of multidrugresistance 1 gene versus neo transduction on ex vivo and in vivo expansion of rhesus macaque hematopoietic repopulating cells. Blood, 97:1888–1891. 2001.
233.
SemenzaGL. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today, 12:853–859. 2007.
234.
SemenzaGL. Hypoxia and human disease. J Mol Med, 85:1293–1294. 2007.
235.
SemenzaGL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer, 3:721–732. 2003.
236.
SevierCS, QuH, HeldmanN, GrossE, FassD, KaiserCA. Modulation of cellular disulfide-bond formation and the ER redox environment by feedback regulation of Ero1. Cell, 129:333–344. 2007.
237.
SharmaR, YangY, SharmaA, AwasthiS, AwasthiYC. Antioxidant role of glutathione S-transferases: protection against oxidant toxicity and regulation of stress-mediated apoptosis. Antioxid Redox Signal, 6:289–300. 2004.
238.
ShusterMI, HanL, Le BeauMM, DavisE, SawickiM, LeseCM, ParkNH, ColicelliJ, GollinSM. A consistent pattern of RIN1 rearrangements in oral squamous cell carcinoma cell lines supports a breakage-fusion-bridge cycle model for 11q13 amplification. Genes Chromosomes Cancer, 28:153–163. 2000.
239.
Sims-MourtadaJ, IzzoJG, AjaniJ, ChaoKS. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene, 26:5674–5679. 2007.
240.
SlovakML, HoJP, ColeSP, DeeleyRG, GreenbergerL, de VriesEG, BroxtermanHJ, SchefferGL, ScheperRJ. The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: evidence that chromosome breakage plays a key role in MRP or LRP gene amplification. Cancer Res, 55:4214–4219. 1995.
241.
SmalleyMJ, ClarkeRB. The mammary gland “side population”: a putative stem/progenitor cell marker?J Mamma Gland Biol Neoplasia, 10:37–47. 2005.
242.
SongIS, TatebeS, DaiW, KuoMT. Delayed mechanism for induction of gamma-glutamylcysteine synthetase heavy subunit mRNA stability by oxidative stress involving p38 mitogen-activated protein kinase signaling. J Biol Chem, 280:28230–28240. 2005.
243.
SprungCN, ReynoldsGE, JasinM, MurnaneJP. Chromosome healing in mouse embryonic stem cells. Proc Natl Acad Sci U S A, 96:6781–6786. 1999.
244.
StyczynskiJ, WysockiM, DebskiR, CzyzewskiK, KolodziejB, RafinskaB, KubickaM, KoltanS, KoltanA, PogorzalaM, KurylakA, Olszewska-SloninaD, BalwierzW, JuraszewskaE, WieczorekM, OlejnikI, Krawczuk-RybakM, KuzmiczM, KowalczykJ, StefaniakJ, BadowskaW, Sonta-JakimczykD, SzczepanskiT, MatysiakM, MalinowskaI, StanczakE, WachowiakJ, KonatkowskaB, GilL, BalcerskaA, Maciejka-KapuscinskaL. Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia. J Cancer Res Clin Oncol, 133:875–893. 2007.
SzotekPP, Pieretti-VanmarckeR, MasiakosPT, DinulescuDM, ConnollyD, FosterR, DombkowskiD, PrefferF, MaclaughlinDT, DonahoePK. Ovarian cancer side population defines cells with stem cell-like characteristics and mullerian inhibiting substance responsiveness. Proc Natl Acad Sci U S A, 103:11154–11159. 2006.
247.
TakadaT, SuzukiH, GotohY, SugiyamaY. Regulation of the cell surface expression of human BCRP/ABCG2 by the phosphorylation state of Akt in polarized cells. Drug Metab Dispos, 33:905–909. 2005.
248.
Takahashi-YanagaF, SasaguriT. The Wnt/beta-catenin signaling pathway as a target in drug discovery. J Pharmacol Sci, 104:293–302. 2007.
249.
TakaraK, SakaedaT, OkumuraK. An update on overcoming MDR1–mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des, 12:273–286. 2006.
250.
TanakaT, UchiumiT, HinoshitaE, InokuchiA, TohS, WadaM, TakanoH, KohnoK, KuwanoM. The human multidrug resistance protein 2 gene: functional characterization of the 5′-flanking region and expression in hepatic cells. Hepatology, 30:1507–1512. 1999.
251.
TatebeS, UnateH, SinicropeFA, SakataniT, SugamuraK, MakinoM, ItoH, SavarajN, KaibaraN, KuoMT. Expression of heavy subunit of gamma-glutamylcysteine synthetase (gamma-GCSh) in human colorectal carcinoma. Int J Cancer, 97:21–27. 2002.
252.
TaylorCT. Mitochondria and cellular oxygen sensing in the HIF pathway. Biochem J, 409:19–26. 2008.
253.
TeeterLD, AtsumiS, SenS, KuoT. DNA amplification in multidrug, cross-resistant Chinese hamster ovary cells: molecular characterization and cytogenetic localization of the amplified DNA. J Cell Biol, 103:1159–1166. 1986.
254.
TeeterLD, BeckerFF, ChisariFV, LiDJ, KuoMT. Over-expression of the multidrug resistance gene mdr3 in spontaneous and chemically induced mouse hepatocellular carcinomas. Mol Cell Biol, 10:5728–5735. 1990.
255.
TeeterLD, EstesM, ChanJY, AtassiH, SellS, BeckerFF, KuoMT. Activation of distinct multidrug-resistance (P-glycoprotein) genes during rat liver regeneration and hepatocarcinogenesis. Mol Carcinog, 8:67–73. 1993.
256.
TienKM, SavarajN. Roles of reactive oxygen species in hepatocarcinogenesis and drug resistance gene expression in liver cancers. Mol Carcinog, 45:701–709. 2006.
257.
TlstyTD, BrownPC, SchimkeRT. UV radiation facilitates methotrexate resistance and amplification of the dihydrofolate reductase gene in cultured 3T6 mouse cells. Mol Cell Biol, 4:1050–1056. 1984.
258.
ToKK, PolgarO, HuffLM, MorisakiK, BatesSE. Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells. Mol Cancer Res, 6:151–164. 2008.
259.
ToledoF, LeRD, ButtinG, DebatisseM. Co-amplified markers alternate in megabase long chromosomal inverted repeats and cluster independently in interphase nuclei at early steps of mammalian gene amplification. EMBO J, 11:2665–2673. 1992.
260.
TothovaZ, KolliparaR, HuntlyBJ, LeeBH, CastrillonDH, CullenDE, McDowellEP, Lazo-KallanianS, WilliamsIR, SearsC, ArmstrongSA, PassegueE, DePinhoRA, GillilandDG. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell, 128:325–339. 2007.
261.
TriantafyllouA, LiakosP, TsakalofA, GeorgatsouE, SimosG, BonanouS. Cobalt induces hypoxia-inducible factor-1alpha (HIF-1alpha) in HeLa cells by an iron-independent, but ROS-, PI-3K- and MAPK-dependent mechanism. Free Radic Res, 40:847–856. 2006.
262.
TuBP, WeissmanJS. Oxidative protein folding in eukaryotes: mechanisms and consequences. J Cell Biol, 164:341–346. 2004.
263.
VafaO, WadeM, KernS, BeecheM, PanditaTK, HamptonGM, WahlGM. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell, 9:1031–1044. 2002.
264.
ValinluckV, TsaiHH, RogstadDK, BurdzyA, BirdA, SowersLC. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2)Nucleic Acids Res, 32:4100–4108. 2004.
265.
van der KolkDM, de VriesEG, MullerM, VellengaE. The role of drug efflux pumps in acute myeloid leukemia. Leukemia Lymphoma, 43:685–701. 2002.
266.
Van WaesC. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res, 13:1076–1082. 2007.
267.
VeluCS, NitureSK, DoneanuCE, PattabiramanN, SrivenugopalKS. Human p53 is inhibited by glutathionylation of cysteines present in the proximal DNA-binding domain during oxidative stress. Biochemistry, 46:7765–7780. 2007.
268.
VersantvoortCH, BroxtermanHJ, BagrijT, ScheperRJ, TwentymanPR. Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. Br J Cancer, 72:82–89. 1995.
269.
VollrathV, WielandtAM, IruretagoyenaM, ChianaleJ. Role of Nrf2 in the regulation of the Mrp2 (ABCC2) gene. Biochem J, 395:599–609. 2006.
270.
WakabayashiK, NakagawaH, AdachiT, KiiI, KobatakeE, KudoA, IshikawaT. Identification of cysteine residues critically involved in homodimer formation and protein expression of human ATP-binding cassette transporter ABCG2: a new approach using the flp recombinase system. J Exp Ther Oncol, 5:205–222. 2006.
271.
WakabayashiK, TamuraA, SaitoH, OnishiY, IshikawaT. Human ABC transporter ABCG2 in xenobiotic protection and redox biology. Drug Metab Rev, 38:371–391. 2006.
272.
Wallace-BrodeurRR, LoweSW. Clinical implications of p53 mutations. Cell Mol Life Sci, 55:64–75. 1999.
273.
WelshSJ, WilliamsRR, BirminghamA, NewmanDJ, KirkpatrickDL, PowisG. The thioredoxin redox inhibitors 1–methylpropyl 2–imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther, 2:235–243. 2003.
274.
WijnholdsJ, EversR, van LeusdenMR, MolCA, ZamanGJ, MayerU, BeijnenJH, vandV, KrimpenfortP, BorstP. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat Med, 3:1275–1279. 1997.
275.
WuC, WeiQ, UtomoV, NadesanP, WhetstoneH, KandelR, WunderJS, AlmanBA. Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Res, 67:8216–8222. 2007.
276.
WuchterC, LeonidK, RuppertV, SchrappeM, BuchnerT, SchochC, HaferlachT, HarbottJ, RateiR, DorkenB, LudwigWD. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica, 85:711–721. 2000.
277.
XuJ, PengH, ChenQ, LiuY, DongZ, ZhangJT. Oligomerization domain of the multidrug resistance-associated transporter ABCG2 and its dominant inhibitory activity. Cancer Res, 67:4373–4381. 2007.
278.
YagiT, SeoBB, Di BernardoS, Nakamaru-OgisoE, KaoMC, Matsuno-YagiA. NADH dehydrogenases: from basic science to biomedicine. J Bioenerg Biomembr, 33:233–242. 2001.
279.
YagueE, ArmesillaAL, HarrisonG, ElliottJ, SardiniA, HigginsCF, RaguzS. P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation. J Biol Chem, 278:10344–10352. 2003.
280.
YamadaT, MoriY, HayashiR, TakadaM, InoY, NaishiroY, KondoT, HirohashiS. Suppression of intestinal polyposis in Mdr1–deficient ApcMin/+ mice. Cancer Res, 63:895–901. 2003.
281.
YamadaT, TakaokaAS, NaishiroY, HayashiR, MaruyamaK, MaesawaC, OchiaiA, HirohashiS. Transactivation of the multidrug resistance 1 gene by T-cell factor 4/betacatenin complex in early colorectal carcinogenesis. Cancer Res, 60:4761–4766. 2000.
282.
YamaneY, FuruichiM, SongR, VanNT, MulcahyRT, IshikawaT, KuoMT. Expression of multidrug resistance protein/GS-X pump and gamma-glutamylcysteine synthetase genes is regulated by oxidative stress. J Biol Chem, 273:31075–31085. 1998.
283.
YangY, ChenQ, ZhangJT. Structural and functional consequences of mutating cysteine residues in the amino terminus of human multidrug resistance-associated protein 1. J Biol Chem, 277:44268–44277. 2002.
284.
YangY, LiuY, DongZ, XuJ, PengH, LiuZ, ZhangJT. Regulation of function by dimerization through the amino-terminal membrane-spanning domain of human ABCC1/MRP12. J Biol Chem, 282:8821–8830. 2007.
285.
YinL, CastagninoP, AssoianRK. ABCG2 expression and side population abundance regulated by a transforming growth factor beta-directed epithelial-mesenchymal transition. Cancer Res, 68:800–807. 2008.
286.
YoshiuraK, KinoshitaA, IshidaT, NinokataA, IshikawaT, KanameT, BannaiM, TokunagaK, SonodaS, KomakiR, IharaM, SaenkoVA, AlipovGK, SekineI, KomatsuK, TakahashiH, NakashimaM, SosonkinaN, MapendanoCK, GhadamiM, NomuraM, LiangDS, MiwaN, KimDK, GaridkhuuA, NatsumeN, OhtaT, TomitaH, KanekoA, KikuchiM, RussomandoG, HirayamaK, IshibashiM, TakahashiA, SaitouN, MurrayJC, SaitoS, NakamuraY, NiikawaN. A SNP in the ABCC11 gene is the determinant of human earwax type. Nat Genet, 38:324–330. 2006.
287.
YuR, ChenC, MoYY, HebbarV, OwuorED, TanTH, KongAN. Activation of mitogen-activated protein kinase pathways induces antioxidant response element-mediated gene expression via a Nrf2–dependent mechanism. J Biol Chem, 275:39907–39913. 2000.
288.
ZelcerN, SaekiT, ReidG, BeijnenJH, BorstP. Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3)J Biol Chem, 276:46400–46407. 2001.
289.
ZelcerN, van deWK, HillebrandM, SartonE, KuilA, WielingaPR, TephlyT, DahanA, BeijnenJH, BorstP. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6–glucuronide antinociception. Proc Natl Acad Sci U S A, 102:7274–7279. 2005.
290.
ZhangDD. Mechanistic studies of the Nrf2–Keap1 signaling pathway. Drug Metab Rev, 38:769–789. 2006.
291.
ZhouS, MorrisJJ, BarnesY, LanL, SchuetzJD, SorrentinoBP. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci U S A, 99:12339–12344. 2002.
292.
ZhouS, SchuetzJD, BuntingKD, ColapietroAM, SampathJ, MorrisJJ, LagutinaI, GrosveldGC, OsawaM, NakauchiH, SorrentinoBP. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med, 7:1028–1034. 2001.
293.
ZhuJ, BlenisJ, YuanJ. Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc Natl Acad Sci U S A, 105:6584–6589. 2008.
294.
ZipperLM, MulcahyRT. Inhibition of ERK and p38 MAP kinases inhibits binding of Nrf2 and induction of GCS genes. Biochem Biophys Res Commun, 278:484–492. 2000.
295.
ZochbauerS, GsurA, BrunnerR, KyrlePA, LechnerK, PirkerR. P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia, 8:974–977. 1994.
296.
ZongY, ZhouS, SorrentinoBP. Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia. Leukemia, 19:1590–1596. 2005.
